MTL-CEBPA

Names

[ CAS No. ]:
2862057-05-2

[ Name ]:
MTL-CEBPA

Biological Activity

[Description]:

MTL-CEPBA is a small activating RNA targeting for upregulation of C/EBPα. MTL-CEPBA has anti-inflammatory and anti-cancer activity[1].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Epigenetics >> MicroRNA

Research Areas >> Inflammation/Immunology

[In Vitro]

MTL-CEBPA does not significantly change total human CD45+ cells, and T lymphocytes (hCD4+ and hCD8+ T cell subsets) in PB. However, MTL-CEBPA treatment increases CD16+ granulocytes and CD14+ monocytes in peripheral blood (PB)[1].

[In Vivo]

MTL-CEBPA (iv; 3 mg/kg; on days 1, 3, and 5) demonstrates the specific activation of its target C/EBPα mRNA and its downstream gene p21 in naive hu-NSG mice[1]. MTL-CEBPA restores LPS-induced (12.5 μg; ip; single dose) reduction of C/EBPα and downregulates several genes associated with immune and inflammatory response in an LPS-stimulated humanized NSG model[1].

[References]

[1]. Jiehua Zhou, et al. Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice. Mol Ther. 2019 May 8;27(5):999-1016.

[2]. Reebye V, Huang KW, Lin V, et al. Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer. Oncogene. 2018;37(24):3216-3228.

[3]. Combination therapies comprising C/EBPα-targeted short-activating RNA (saRNA). WO2022229644A1

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.